Ortho Clinical Diagnostics Holdings plc (OCDX)
| Market Cap | 4.62B |
| Revenue (ttm) | 1.77B |
| Net Income (ttm) | -211.90M |
| Shares Out | 222.58M |
| EPS (ttm) | -0.95 |
| PE Ratio | n/a |
| Forward PE | 30.77 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 12 |
| Last Price | $20.75 |
| Previous Close | $21.27 |
| Change ($) | -0.52 |
| Change (%) | -2.44% |
| Day's Open | 20.95 |
| Day's Range | 20.74 - 21.49 |
| Day's Volume | 615,315 |
| 52-Week Range | 15.14 - 21.82 |
First Quarter Revenue Growth Exceeds Company's Expectations at 24.2%, Supporting Increase in 2021 Guidance First Quarter Revenue Growth Exceeds Company's Expectations at 24.2%, Supporting Increase in 20...
- Ortho's VITROS® Anti-SARS-CoV-2 IgG Quantitative Antibody test is traceable to the WHO International Standard for anti-SARS-CoV-2 IgG antibodies, which is developed to facilitate the standardization o...
ORTHO VISION is the leading choice for blood banks RARITAN, N.J., May 3, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics compani...
RARITAN, N.J., April 26, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (NASDAQ: OCDX), one of the world's largest pure-play in vitro diagnostics (IVD) companies, has been recognized with a prestigious...
RARITAN, N.J., April 21, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced it will report results f...
RARITAN, N.J., April 13, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced it received CE Marking for i...
- The new contract will deliver Ortho with funding for capacity expansion to provide up to 6.7 million COVID-19 tests per month dedicated for the U.S. market over the next 12-14 months RARITAN, N.J., M...
RARITAN, N.J., March 23, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced it received authorization fr...
Fourth Quarter Revenue Growth Ahead of Company Expectations at 9.1% Fourth Quarter Revenue Growth Ahead of Company Expectations at 9.1%
Fourth Quarter Revenue Growth Ahead of Company Expectations at 9.1% Fourth Quarter Revenue Growth Ahead of Company Expectations at 9.1%
Last year was a monster year for the initial public offering market, and 2021 looks like it could provide a repeat performance.
RARITAN, N.J., March 8, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play IVD companies dedicated to transforming patient care, today announced that it...
RARITAN, N.J., March 04, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics (IVD) companies dedicated to transform...
Former CEO of Charles Schwab Investment Management will also serve as audit committee chair Former CEO of Charles Schwab Investment Management will also serve as audit committee chair
Agencies Provide Stable Outlook Following Company's Initial Public Offering Agencies Provide Stable Outlook Following Company's Initial Public Offering
Increases facility by $150 million and extends it to 2026
RARITAN, N.J., Feb. 4, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) ("Ortho"), the world's largest pure-play in vitro diagnostics company dedicated to improving and saving...
After its shares fell nearly 7% in a public debut last week, Ortho Clinical Diagnostics Holdings PLC (NASDAQ:OCDX) is clawing its way back to a modicum of respectability. The Raritan, New Jersey-based c...
RARITAN, N.J., Jan. 27, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics Holdings plc ("Ortho"), the world's largest pure-play in vitro diagnostics company dedicated to improving and saving lives through...
Ortho Clinical Diagnostics Holdings plc ("Ortho"), the world's largest pure-play in vitro diagnostics company dedicated to improving and saving...
Ortho Clinical Diagnostics, a Carlyle-backed global provider of in vitro diagnostic products, filed on Monday with the SEC to raise up to $100 million in an initial public offering. However, this is lik...
Ortho Clinical Diagnostics Holdings plc has filed to go public with an IPO on the NASDAQ.
About OCDX
Ortho Clinical Diagnostics is a pure-play in vitro diagnostics (“IVD”) business driven by our credo, “Because Every Test is A Life.” This guiding principle reflects the crucial role diagnostics play in global health and guides our priorities as an organization. As a leader in IVD, we impact approximately 800,000 patients every day. We are dedicated to improving outcomes for these patients and saving lives through providing innovative and reliable diagnostic testing solutions to the clinical laboratory and transfusion medicine communitie... [Read more...]
| Industry Diagnostics & Research | IPO Date Jan 28, 2021 |
| CEO Chris Smith | Employees 4,500 |
| Stock Exchange NASDAQ | Ticker Symbol OCDX |
Financial Performance
In 2020, OCDX's revenue was $1.77 billion, a decrease of -1.96% compared to the previous year's $1.80 billion. Losses were -$211.90 million, 35.1% more than in 2019.
Analyst Forecasts
The average 12-month stock price forecast for OCDX is 24.45, which is an increase of 17.83% from the latest price.